Are you Dr. Yu?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 39 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
50 N Medical Dr
Salt Lake City, UT 84132Phone+1 801-581-2121
Summary
- Dr. Margaret Yu, MD is an oncologist in Salt Lake City, Utah. She is currently licensed to practice medicine in Utah and California.
Education & Training
University of Utah HealthFellowship, Hematology and Medical Oncology, 2000 - 2003- University of Utah HealthResidency, Internal Medicine, 1997 - 2000
Medical College of WisconsinClass of 1997
Certifications & Licensure
CA State Medical License 2016 - 2025
UT State Medical License 1998 - 2018
Publications & Presentations
PubMed
- 780 citationsApalutamide Treatment and Metastasis-free Survival in Prostate CancerMatthew R. Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris Hadaschik
The New England Journal of Medicine. 2018-02-08 - 66 citationsAndrogen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.Dana E. Rathkopf, Matthew R. Smith, Charles J. Ryan, William R. Berry, N.D. Shore
Annals of Oncology. 2017-09-01 - 916 citationsAbiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final o...Charles J. Ryan, Matthew R. Smith, Karim Fizazi, Fred Saad, Peter F.A. Mulders
The Lancet. Oncology. 2015-02-01
Press Mentions
Updated Results of the SPARTAN Study Show 25 Percent Reduction in the Risk of Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) Treated with ERLEADA® (Apalutamide)December 19th, 2019
Erleada Cuts Risk of Death by 25% in Localized Castration-Resistant Prostate Cancer, Phase 3 Trial FindsOctober 2nd, 2019
Updated Results of the SPARTAN Study Show 25 Percent Reduction in the Risk of Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) Treated with ERLEADA® (Apalutamide)September 27th, 2019- Join now to see all
